Floatz logo

VINCRISTINE SULFATE

Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged

Children's Oncology GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged cohort.

Asset / SponsorPhaseRating
Revumenib
National Cancer Institute (NCI)
Phase 2B
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2B
Solu-Cortef
Children's Oncology Group
Phase 2CCC
Calaspargase Pegol
Children's Oncology Group
Phase 2CCC
Fludarabine
Children's Oncology Group
Phase 2CCC

View all 14 →

Same molecule, other indications

VINCRISTINE SULFATE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
diffuse large B-cell lymphomaDormant
A
Indicative ·
80 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →